Buscar
-
GRK2‐ Targeted Knockdown as Therapy for Multiple System Atrophy
(Movement Disorders. vol. 38, n° 7, pp. 1336-1340, 2023-07)Article de revueLibre acceso -
PLGA-Based Nanoparticles for Neuroprotective Drug Delivery in Neurodegenerative Diseases
(Pharmaceutics. vol. 13, n° 7, 2021-07-08)Article de revueLibre acceso -
Striatopallidal cannabinoid type-1 receptors mediate amphetamine-induced sensitization
(2023-10)Document de travail - Pré-publicationLibre acceso -
Assessment of Mendelian and risk factor genes in Alzheimer disease: a prospective nationwide clinical utility study and recommendations for genetic screening
(Genetics in Medicine. pp. 101082, 2024-01-24)Article de revueLibre acceso -
Craving dynamics and related cerebral substrates predict timing of use in alcohol, tobacco, and cannabis use disorders
(Addiction Neuroscience. vol. 9, 2023-12-15)Article de revueLibre acceso -
Patient-perceived progression in multiple system atrophy: natural history of quality of life
(Journal of Neurology, Neurosurgery and Psychiatry, 2024-03-07)Article de revueLibre acceso -
Camkiiβ in neuronal development and plasticity: An emerging candidate in brain diseases
(International Journal of Molecular Sciences. vol. 21, n° 19, pp. 1-15, 2020-10-01)Article de revueLibre acceso -
Structural progression of Alzheimer's disease over decades: The MRI staging scheme
(Brain Communications. vol. 4, n° 3, 2022-04-28)Article de revueLibre acceso -
The Unified Multiple System Atrophy Rating Scale: Status, Critique, and Recommendations
(Movement Disorders. vol. 37, n° 12, pp. 2336-2341, 2022-09-08)Article de revueLibre acceso -
Lifespan neurodegeneration of the human brain in multiple sclerosis
(Human Brain Mapping. vol. 44, n° 17, pp. 5602-5611, 2023-03-14)Article de revueLibre acceso